Thermo Fisher Scientific names Jim Meyer as new CFO

WALTHAM, Mass. - Thermo Fisher Scientific Inc. (NYSE:TMO), a $161.4 billion market cap company with a GOOD financial health score according to InvestingPro, announced Wednesday that Stephen Williamson, senior vice president and chief financial officer, will retire effective March 31, 2026. Jim Meyer, currently vice president of financial operations, will succeed Williamson as CFO beginning March 1, 2026.

Williamson, 58, has served as CFO since 2015 and has been with the company since 2001. During his tenure, Thermo Fisher’s market capitalization increased nearly 300 percent, while maintaining strong shareholder returns through consistent dividend payments for 14 consecutive years and aggressive share buybacks, as noted in InvestingPro’s analysis.

Meyer, 46, joined Thermo Fisher in 2009 and has held various finance leadership positions within the company. He was appointed vice president of financial operations in January 2023, overseeing finance support for all operating businesses. Prior to joining Thermo Fisher, Meyer worked at PricewaterhouseCoopers.

Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher, stated that Meyer’s appointment is part of a "long-planned succession process" and cited Meyer’s "strong financial expertise and deep company knowledge."

To ensure a smooth transition, Williamson and Meyer will work together over the coming months. Williamson will remain on the Company Leadership Team until his retirement.

Thermo Fisher Scientific, which describes itself as "the world leader in serving science," reported annual revenue of $42.9 billion with a healthy gross profit margin of 41.4%. The company maintains its position as a prominent player in the Life Sciences Tools & Services industry, trading at a P/E ratio of 25x. For detailed financial analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Thermo Fisher Scientific has announced plans to acquire Sanofi’s sterile manufacturing facility in New Jersey, aiming to enhance its drug production capabilities in the United States. This acquisition, expected to close in the latter half of 2025, will bring over 200 employees from the facility into Thermo Fisher’s workforce. Additionally, Thermo Fisher declared a quarterly dividend of $0.43 per share, payable in October 2025, reflecting its commitment to returning value to shareholders. The company reported annual revenue exceeding $40 billion, highlighting its substantial market presence.

In terms of stock analysis, Scotiabank upgraded Thermo Fisher’s rating to Sector Outperform, setting a price target of $590. This upgrade is based on the belief that the company’s shares have been disproportionately affected by U.S. healthcare and trade policy discussions. Meanwhile, TD Cowen adjusted its price target for Thermo Fisher to $550, maintaining a Buy rating and expecting the company’s performance to align with market expectations.

Furthermore, Thermo Fisher’s Board of Directors has granted CEO Marc N. Casper performance-based restricted stock units valued at approximately $60 million. These units are part of a long-term incentive plan designed to retain Casper’s leadership and drive shareholder returns. The performance period for these stock units extends until the end of 2029, contingent on Casper’s continued leadership role.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.